Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 5.66 -3.08% -0.18
ARDS closed down 3.08 percent on Thursday, April 15, 2021, on 25 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ARDS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -3.08%
Outside Day Range Expansion -3.08%
Wide Bands Range Expansion -3.08%
Oversold Stochastic Weakness -3.08%
New 52 Week Closing Low Bearish 6.79%
Narrow Range Bar Range Contraction 6.79%
Older End-of-Day Signals for ARDS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 17 hours ago
Rose Above Previous Day's High about 17 hours ago
20 DMA Resistance about 17 hours ago
Down 2 % about 17 hours ago
Down 1% about 17 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aridis Pharmaceuticals Inc. Description

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Infectious Diseases Immunotherapy Antibodies Monoclonal Antibody Monoclonal Antibodies Bacterial Infections Healthcare Associated Infections Infections Bacterial Diseases Pneumonia Staphylococcus Aureus Human Monoclonal Antibodies Pathogenic Bacteria Drug Resistance Pseudomonas Aeruginosa Immunoglobulin M Targeted Immunotherapy

Is ARDS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.18
52 Week Low 4.7
Average Volume 36,988
200-Day Moving Average 6.85
50-Day Moving Average 6.56
20-Day Moving Average 6.04
10-Day Moving Average 5.70
Average True Range 0.52
ADX 18.65
+DI 19.90
-DI 22.94
Chandelier Exit (Long, 3 ATRs ) 6.30
Chandelier Exit (Short, 3 ATRs ) 6.76
Upper Bollinger Band 7.04
Lower Bollinger Band 5.03
Percent B (%b) 0.31
BandWidth 33.26
MACD Line -0.29
MACD Signal Line -0.27
MACD Histogram -0.0224
Fundamentals Value
Market Cap 56.97 Million
Num Shares 10.1 Million
EPS -4.19
Price-to-Earnings (P/E) Ratio -1.35
Price-to-Sales 58.17
Price-to-Book 5.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.26
Resistance 3 (R3) 6.33 6.19 6.16
Resistance 2 (R2) 6.19 6.04 6.16 6.13
Resistance 1 (R1) 5.93 5.95 5.86 5.86 6.09
Pivot Point 5.79 5.79 5.76 5.76 5.79
Support 1 (S1) 5.53 5.64 5.46 5.46 5.23
Support 2 (S2) 5.39 5.55 5.36 5.19
Support 3 (S3) 5.13 5.39 5.16
Support 4 (S4) 5.06